Percutaneous circulatory support market seen reaching $3.87 billion by 2030

The market for percutaneous mechanical circulatory support devices is projected to grow from $2.7 billion in 2026 to $3.87 billion by 2030, driven by rising cardiovascular disease, more cardiogenic shock cases and wider use of minimally invasive cardiac care. North America led the market in 2025, while the report highlights AI-assisted monitoring, pump advances and faster-deploying support systems as key trends.

Why it matters: - Percutaneous mechanical circulatory support devices are becoming more important in treating acute heart failure, cardiogenic shock and high-risk cardiac procedures. - The market’s projected rise to $3.87 billion by 2030 signals growing demand for temporary heart support in hospitals and catheterization labs. - The growth trend reflects broader pressure on health systems as cardiovascular disease rates and cardiac complications increase worldwide.

What happened: - The Business Research Company released a report on the global percutaneous mechanical circulatory support devices market. - The market was valued at $2.46 billion in 2025 and is forecast to reach $2.7 billion in 2026. - The report projects the market will reach $3.87 billion by 2030. - The report says the market is expected to grow at a 9.7% CAGR in 2026 and 9.4% CAGR through 2030. - North America held the largest regional share in 2025. - The report covers Asia-Pacific, South East Asia, Western Europe, Eastern Europe, South America, the Middle East and Africa. - The Business Research Company offers a free sample report and the full market report.

The details: - Percutaneous mechanical circulatory support, or pMCS, devices are minimally invasive tools designed to temporarily assist or fully replace the heart’s pumping function. - The devices are typically inserted through a catheter via blood vessels, most often the femoral artery. - pMCS devices are positioned within the heart to provide mechanical support during critical cardiac events. - Historical market growth has been driven by higher cardiovascular disease rates, more cardiogenic shock cases, wider adoption of minimally invasive treatments, expanding ICU capacity and an aging population. - Future growth is expected to be supported by AI-assisted cardiac monitoring, more complex cardiac procedures, broader use of catheterization labs, rising demand for temporary heart support and pump technology advances. - The report flags several emerging product categories, including minimally invasive cardiac support systems, short-term hemodynamic assistance devices, support tools for high-risk percutaneous coronary interventions, rapid deployment cardiac platforms and patient-safety-focused designs. - The report says cardiovascular diseases include coronary artery disease, heart attacks, heart failure, strokes and hypertension. - The report links rising CVD rates to aging populations, unhealthy lifestyles, obesity, high blood pressure and genetic factors. - In October 2024, the Centers for Disease Control and Prevention reported that about one in six cardiovascular disease deaths in 2023 occurred in adults younger than 65. - The CDC said 919,032 deaths were attributed to cardiovascular disease in 2023, accounting for one-third of all deaths.

Between the lines: - The market forecast points to a shift toward earlier, faster and less invasive cardiac intervention. - The report’s emphasis on AI, rapid deployment and catheter-based support suggests hospitals are looking for tools that can stabilize patients quickly and reduce procedural risk. - The North America lead indicates the region’s advanced cardiac care infrastructure and adoption of high-cost devices remain important market advantages.

What's next: - The Business Research Company expects growth to continue as hospitals expand access to catheter-based cardiac support and adopt newer pump technologies. - The report points to stronger use cases in complex PCI, temporary support and critical-care settings over the next several years. - The company says its 2026 reports now include market attractiveness scoring, TAM analysis, company scoring matrix graphics, Excel-based forecasting dashboards, hotspot infographics and updated technology trend analysis.

The bottom line: - pMCS devices are moving from niche critical-care tools to a larger global market shaped by aging populations, rising cardiovascular disease and demand for minimally invasive heart support.